PENNVAX-GP (HIV DNA vaccine) / Inovio - LARVOL DELTA

Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - P1/2; N=56; Completed; Sponsor: Steven Deeks; Active, not recruiting ➔ Completed; Trial completion date: Dec 2022 ➔ May 2021; Trial primary completion date: Dec 2021 ➔ May 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - P1/2; N=56; Active, not recruiting; Sponsor: Steven Deeks; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. (PubMed, Vaccines (Basel)) - "ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Pain

Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Steven Deeks; Trial completion date: Dec 2020 ➔ Dec 2022; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Robust antibody and cellular responses induced by DNA-only vaccination for HIV. (PubMed, JCI Insight) - P1 | "PENNVAX®-GP DNA induced robust cellular and humoral immune responses, demonstrating that immunogenicity of DNA vaccines can be enhanced by EP route and inclusion of pIL-12. ID/EP was dose-sparing, inducing equivalent, or in some aspects superior, immune responses compared to IM/EP."

Journal • Allergy • Gene Therapies • Immunology • Infectious Disease • CD8 • IL12A • IL2